Optimising the Medical Management of Benign Prostatic Hyperplasia
- 1 April 2004
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 45 (4) , 411-419
- https://doi.org/10.1016/j.eururo.2003.10.016
Abstract
No abstract availableThis publication has 66 references indexed in Scilit:
- 5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related SurgeryPublished by Elsevier ,2004
- Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2003
- Drug Treatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related SurgeryEuropean Urology, 2003
- Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of AgingJournal of Urology, 2002
- THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSEJournal of Urology, 1998
- Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 1998
- A cost density analysis of benign prostatic hyperplasiaClinical Therapeutics, 1996
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study GroupArchives of Family Medicine, 1993
- Impact of benign prostatic hyperplasia on general well‐being of menThe Prostate, 1993